GHRP-6
GHRP6
Ghrelin-receptor secretagogue that increases GH and notably stimulates appetite.
Overview
GHRP-6 is a first-generation growth hormone secretagogue that acts on the ghrelin (GHS-R1a) receptor to amplify growth hormone pulses from the pituitary. Unlike GHRH analogs, it works through a separate pathway, which is why stacking the two classes produces a stronger GH response than either alone. Its defining feature beyond GH release is appetite stimulation, a direct consequence of ghrelin-receptor activation, which makes it the appetite-heavy member of the GHRP family. The estimated half-life is roughly one hour with around 50% subcutaneous bioavailability, so research contexts typically reference multiple daily doses. Human pharmacokinetic data is limited and GHRP-6 is not an approved medication.
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 0.0 days
- Bioavailability
- 50%
- Typical dose
- 0.1–0.3 mg
Related compounds
Ipamorelin
Selective GHRP secretagogue releasing growth hormone with relatively minimal cortisol/prolactin effect.
GHRP-2
Growth hormone secretagogue that acts on the ghrelin receptor to amplify GH pulses.
MK-677 (Ibutamoren)
Orally active growth hormone secretagogue (ghrelin receptor agonist) that elevates GH and IGF-1; the non-peptide counterpart to injectable GHRPs.
Comments
Loading comments…